|
Parameters
|
Univarite analysis
|
Multivariate analysis
|
|---|
|
Hazard ratio
|
95% CI
|
p value
|
Hazard ratio
|
95% CI
|
p value
|
|---|
|
Age at opetation (years)
|
|
≤ 45 vs > 60
|
0.813
|
0.524–1.255
|
0.346
| | | |
|
Tumor size (mm)
|
|
≤ 20 vs > 20
|
1.188
|
0.402–5.074
|
0.778
| | | |
|
Skin infiltration
|
|
Negative vs positive
|
5.034
|
1.940–12.433
|
0.002
|
6.899
|
2.467–18.908
|
< 0.001
|
|
Lymph node status
|
|
Negative vs positive
|
4.239
|
1.227–26.631
|
0.019
|
2.999
|
0.815–19.389
|
0.106
|
|
Estrogen receptor
|
|
Negative vs positive
|
0.474
|
0.169–1.167
|
0.107
| | | |
|
Progesterone receptor
|
|
Negative vs positive
|
0.475
|
0.137–1.285
|
0.151
| | | |
|
Hormone receptor
|
|
Negative vs positive
|
0.441
|
0.157–1.085
|
0.076
| | | |
|
HER2
|
|
Negative vs positive
|
0.283
|
0.066–0.844
|
0.021
|
0.721
|
0.149–2.809
|
0.645
|
|
Intrinsic subtype
|
|
Not TNBC vs TNBC
|
3.966
|
1.640–10.130
|
0.002
|
3.703
|
1.323–11.575
|
0.012
|
|
Ki67
|
|
≤ 14% vs >14%
|
2.730
|
1.004–9.518
|
0.049
|
2.271
|
0.768–8.314
|
0.144
|
|
Objective response rate
|
|
Non-responders vs responders
|
0.244
|
0.097–0.692
|
0.010
|
0.259
|
0.090–0.797
|
0.020
|
|
Pathological response
|
|
Non-pCR vs pCR
|
0.241
|
0.056–0.718
|
0.009
|
0.384
|
0.082–1.332
|
0.137
|
|
TILs
|
|
Low vs high
|
0.578
|
0.232–1.380
|
0.216
| | | |
- OS overall survival, CI confidence intervals, HER human epidermal growth factor receptor, pCR pathological complete response, TILs tumor-infiltrating lymphocytes
